These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 16012011)
41. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817 [TBL] [Abstract][Full Text] [Related]
42. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study. Stewardson AJ; Vervoort J; Adriaenssens N; Coenen S; Godycki-Cwirko M; Kowalczyk A; Huttner BD; Lammens C; Malhotra-Kumar S; Goossens H; Harbarth S; ; Clin Microbiol Infect; 2018 Sep; 24(9):972-979. PubMed ID: 29331548 [TBL] [Abstract][Full Text] [Related]
43. [Epidemiological aspects relating to the determination of fosfomycin sensitivity: results of a study on 300 strains isolated in a hospital milieu in Turin]. Vanini GC; Moiraghi Ruggenini A; Grassi R; Maury F; Giardini F G Batteriol Virol Immunol; 1979; 71(1-6):73-84. PubMed ID: 488578 [TBL] [Abstract][Full Text] [Related]
53. Fluoroquinolones for urinary tract infection and within-household spread of resistant Enterobacteriaceae: the smoking gun. Trautner BW Clin Microbiol Infect; 2018 Sep; 24(9):929-930. PubMed ID: 29649605 [No Abstract] [Full Text] [Related]
54. [Community-acquired urinary tract infections in 15 to 65 years old female patients in France. Susceptibility of E. coli according to history: AFORCOPI-BIO network 2003]. de Mouy D; Fabre R; Cavallo JD; Arzouni JP; Baynat M; Bicart-See A; Berges JL; Bouilloux JP; Galinier JL; Garrabé E; Gontier P; Grillet N; Lepargneur JP; Naepels I; Payro G; Med Mal Infect; 2007 Sep; 37(9):594-8. PubMed ID: 17258415 [TBL] [Abstract][Full Text] [Related]
55. [In vitro antibacterial activity of fosfomycin]. Giola L; Rizzu D; Zanetti S G Batteriol Virol Immunol; 1979; 71(1-6):34-40. PubMed ID: 385409 [TBL] [Abstract][Full Text] [Related]
56. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. Corkill JE; Anson JJ; Hart CA J Antimicrob Chemother; 2005 Dec; 56(6):1115-7. PubMed ID: 16260446 [TBL] [Abstract][Full Text] [Related]
57. [Prevalence and dispersion of plasmids conferring fosfomycin resistance in enterobacteria]. Hardisson C; Villar CJ; Llaneza J; Mendoza MC Pathol Biol (Paris); 1984 Sep; 32(7):755-8. PubMed ID: 6387596 [TBL] [Abstract][Full Text] [Related]
58. [The role of the culture medium in the sensitivity of Gram-negative stocks and their resistant mutants to fosfomycin. The influence of glucose-6-phosphate]. Drugeon H; Courtieu AL Minerva Med; 1978 Dec; 69(59):4055-60. PubMed ID: 105326 [No Abstract] [Full Text] [Related]
59. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? Miller LG; Mehrotra R; Tang AW Int J Antimicrob Agents; 2007 May; 29(5):605-7. PubMed ID: 17293087 [No Abstract] [Full Text] [Related]